9Hazmarna S, Oka M, Yoshino S, et al. Clinical effects and immunological analysis of intraabdominal and intraplenral injection of lentinan for malignant ascites and pleural effusion of gastric carcionoma [J]. Gam To Kagakn Ryoho,1995,22(11) :1595.
3Heffner JE,Klein JS. Recent advances in the diagnosis andmanagement of malignant pleural effusions. Mayo Clin Proc,2008,83(2) :235-250.
4Musani AI.Treatment options for malignant pleural effusion. Current Opinion in Pulmonary Medicine . 2009
5KAWAOKA T,YOSHINO S,HAZAMA S,et al.Clinicalevaluation of intrapleural or peritoneal administration of lentin-an and OK-432 for malignant effusion. Gan To Kagaku Ryono . 2003
6Decroisette C, Galerneau LM, Hominal S, et al. Epidemiology, man- agement and cost of bone metastases from lung cancer[J]. Rev Mal Respir,2013,30(4) :309 - 315.
7Dresler C. The changing epidemic of lung cancer and occupational and environmental risk factors[ J]. Thorac Surg Clin ,2013,23 (2) : 113 -122.
8Tiwana MS, Lee HN, Saini S,et al. Outcomes of patients with unre- sected stage III and stage IV non - small cell lung cancer: A single institution experience [ J ]. Lung India,2013,30 ( 3 ) : 187 - 192.
9Luo J, Chen Y J, Narsavage GL, et al. Predictors of survival in pa- tients with non - small cell lung cancer [ J ]. Oncol Nurs Forum, 2012,39(6) :609 -616.
10Jaume Trapé,Rafael Molina,Francesc Sant,Jesús Montesinos,Anna Arnau,Josefina Franquesa,Rosana Blavia,Esperanza Martín,Emili Marquilles,Damià Perich,Concepción Pérez,Josep Maria Roca,Montserrat Doménech,Joan López,Josep Miquel Badal.Diagnostic accuracy of tumour markers in serous effusions: a validation study[J].Tumor Biology.2012(5)
